Latest Comments
-
jonsjon1223 on Calistoga and Plexxikon: Gone in The Blink Of An Eye So should we buy Daichi Sankyo (it doesn't trad...
-
Jason Chew on Calistoga and Plexxikon: Gone in The Blink Of An Eye Still think Fed's gonna be super conservative w...
-
JPG101 on Calistoga and Plexxikon: Gone in The Blink Of An Eye Everything was 'fine' before Lehman... until it...
-
Jason Chew on Calistoga and Plexxikon: Gone in The Blink Of An Eye www.bioworld.com/servl...Hey, the world isn't c...
-
JPG101 on Calistoga and Plexxikon: Gone in The Blink Of An Eye What do you mean by: Pharma been pulling out of...
Most Commented
- Calistoga and Plexxikon: Gone in The Blink Of An Eye (19 Comments)
- Why Arena’s Lorcaserin Will Not Be Used In Combination With Phentermine (6 Comments)
- Four Emerging Taiwan Drug Developers (5 Comments)
- Incyte’s Topical JAK Inhibitor: Throw it Over the Counter (2 Comments)
- Calistoga Pharmaceuticals and Plexxikon- Two Biotechs to Keep an Eye On (2 Comments)
Posts by Themes
5-HT,
A-002,
Abraxis,
Acquisition,
ADC,
aHUH,
AKT,
ALCL,
Alexion,
ANDA,
anti-TNF,
Antibodies Therapeutics,
Antibody Drug Conjugate,
Antibody-Drug-Conjugate,
Antisense,
ASH,
Authorized Generics,
Avanir,
B-RAF,
Biogen,
Biologics,
Bioscience,
Biosimilars,
Biotech,
boceprevir,
Branded Generics,
Brands,
business cycle,
business model,
Business Model,
Business model,
Cancer Stem Cells,
Cancer Vaccine,
cardiovascular disease,
CD30,
CD70,
CDX-110,
Celldex,
Celldex CDX-110 CDX-011 GBM Breast Cancer,
CEO,
China,
clinical trial,
Clinical Trials,
CML,
Collaboration,
combination therapy,
Complement C5,
CRO,
Cubicin,
Curis,
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
















Full Index of Posts 27 posts, page 1 of 1
POZEN Gets Going With Licensing Deal, Positive Clinical Data
Why is Exelixis Shrinking?
Calistoga and Plexxikon: Gone in The Blink Of An Eye
Genzyme Sold, Who’s Next?
GSK Pursues Fabry Disease Drug as Orphan Indications Are All The Rage
Idenix: Two Steps Forward and One Step Back
RNAi: Is It Still Worth Investing?
Vivus- Last One Standing
Celgene: Is It Time To Buy?
Of Billionaires and Biotechs
Biovista – a Dedicated Approach to Drug Repositioning
MagForce- Revolutionizing Cancer Treatment With Nanotechnology
Pharma Emulating Biotech to Boost R&D Productivity
Are Generics Killing Drug Innovation?
The Rx to OTC Switch: Growth Opportunities for Brand Name Drugs
Incyte’s Topical JAK Inhibitor: Throw it Over the Counter
Bringing Innovation Back to Bioscience Research
The Rise of China as a Bioscience Leader
Is Pharma Over Invested in Antibody Therapeutics?
Garage Biotechs: The Modern Day Startup
Four Emerging Taiwan Drug Developers
Taiwan Liposome Company- Ahead of the Pack
Why Arena’s Lorcaserin Will Not Be Used In Combination With Phentermine
Calistoga Pharmaceuticals and Plexxikon- Two Biotechs to Keep an Eye On
Vivus Has a Hit with Qnexa
The Promise Behind Celldex
Incyte Pharmaceuticals- The Next Big Thing?